

CITATION REPORT

List of articles citing

Treatment of nonalcoholic steatohepatitis with probiotics. A proof-of-concept study

DOI: 10.1016/s1665-2681(19)31364-x
Annals of Hepatology, 2013, 12, 256-262.

Source: <https://exaly.com/paper-pdf/57254900/citation-report.pdf>

Version: 2024-04-27

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
222	Non-alcoholic steatohepatitis: pathogenesis and novel therapeutic approaches. 2013 , 28 Suppl 1, 68-76		170
221	Non-alcoholic steatohepatitis: a microbiota-driven disease. 2013 , 24, 537-45		118
220	More on current evidences on probiotics as a novel treatment for non-alcoholic Fatty liver disease. 2013 , 13, e13780		1
219	Effects of probiotics on nonalcoholic fatty liver disease: a meta-analysis. 2013 , 19, 6911-8		227
218	Molecular characterization of the fecal microbiota in patients with nonalcoholic steatohepatitis--a longitudinal study. 2013 , 8, e62885		205
217	Hepatology highlights. <i>Annals of Hepatology</i> , 2013 , 12, 170-172	3.1	1
216	Is there a role for probiotics in liver disease?. 2014 , 2014, 874768		15
215	The role of intestinal bacteria overgrowth in obesity-related nonalcoholic fatty liver disease. 2014 , 6, 5583-99		65
214	Concepts and Treatment Approaches in Nonalcoholic Fatty Liver Disease. 2014 , 2014, 1-7		2
213	A Review of Fatty Liver/NASH and Liver Cirrhosis: Genetics, Prevention, Nutritional, Behavioral Modification, Exercise, Pharmaceutical, Biophysics and Biotech Therapy. 2014 , 3,		1
212	Gut-liver axis and probiotics: their role in non-alcoholic fatty liver disease. 2014 , 20, 15518-31		111
211	Non-alcoholic fatty liver disease: what the clinician needs to know. 2014 , 20, 12956-80		117
210	Pharmacologic Management of Non-Alcoholic Fatty Liver Disease. 2014 , 03,		1
209	Probiotics and synbiotics may improve liver aminotransferases levels in non-alcoholic fatty liver disease patients. <i>Annals of Hepatology</i> , 2014 , 13, 482-488	3.1	30
208	Meta-omic platforms to assist in the understanding of NAFLD gut microbiota alterations: tools and applications. 2014 , 15, 684-711		21
207	Management of fatty liver disease with the metabolic syndrome. 2014 , 8, 487-500		21
206	Randomised clinical trial: The beneficial effects of VSL#3 in obese children with non-alcoholic steatohepatitis. 2014 , 39, 1276-85		269

205	Probiotics to Treat Visceral Obesity and Related Liver Disease. 2014 , 363-380	1
204	Integrative Weight Management. 2014 ,	2
203	Are oxidative stress mechanisms the common denominator in the progression from hepatic steatosis towards non-alcoholic steatohepatitis (NASH)?. 2014 , 34, e180-90	73
202	Nonalcoholic Fatty Liver Disease. 2014 , 145-169	1
201	More evidence that probiotics may have a role in treating fatty liver disease. 2014 , 99, 425-6	4
200	NASH and the Cross-Talk Between the Gut and Liver. 2014 , 2, 211-217	1
199	Review article: the management of paediatric nonalcoholic fatty liver disease. 2014 , 40, 1155-70	33
198	Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease. 2014 , 20, 16841-57	31
197	Systematic review: microbial dysbiosis and nonalcoholic fatty liver disease. 2015 , 42, 1051-63	122
196	Gut microbiome and liver diseases. 2015 , 411-420	1
195	Alcoholic, Nonalcoholic, and Toxicant-Associated Steatohepatitis: Mechanistic Similarities and Differences. 2015 , 1, 356-367	48
194	Probiotics in Nonalcoholic Fatty Liver Disease, Nonalcoholic Steatohepatitis, and Cirrhosis. 2015 , 49 Suppl 1, S28-32	12
193	Probiotics in Pediatric Liver Disease. 2015 , 49 Suppl 1, S33-6	9
192	Recommendations for Probiotic Use--2015 Update: Proceedings and Consensus Opinion. 2015 , 49 Suppl 1, S69-73	83
191	Gut microbiota and liver diseases. 2015 , 21, 1691-702	94
190	Probiotics as a complementary therapeutic approach in nonalcoholic fatty liver disease. 2015 , 7, 559-65	29
189	Treatment of nonalcoholic steatohepatitis in adults: present and future. 2015 , 2015, 732870	19
188	Systematic review on intervention with prebiotics/probiotics in patients with obesity-related nonalcoholic fatty liver disease. 2015 , 10, 889-902	79

187	Gut microbiota and non-alcoholic fatty liver disease. 2015 , 14, 572-81	45
186	Gut-liver axis, nutrition, and non-alcoholic fatty liver disease. 2015 , 48, 923-30	165
185	Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease. 2015 , 35, 221-35	235
184	Role of the Gut Microbiome in Nonalcoholic Fatty Liver Disease. 2015 , 30, 780-6	27
183	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanism and Application of Metabolomics. 2016 , 17, 300	49
182	Diet, Microbiota, Obesity, and NAFLD: A Dangerous Quartet. 2016 , 17, 481	70
181	Effects of Probiotics and Synbiotics on Obesity, Insulin Resistance Syndrome, Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease: A Review of Human Clinical Trials. 2016 , 17,	160
180	Beneficial Effect of Synbiotic Supplementation on Hepatic Steatosis and Anthropometric Parameters, But Not on Gut Permeability in a Population with Nonalcoholic Steatohepatitis. 2016 , 8,	60
179	Precision medicine in alcoholic and nonalcoholic fatty liver disease via modulating the gut microbiota. 2016 , 311, G1018-G1036	49
178	A Bugs Battle on Behalf of the Liver. 2016 , 23, 126-129	
177	Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1365-74	72
176	Emerging and future therapies for nonalcoholic steatohepatitis in adults. 2016 , 17, 1937-46	29
175	Probiotic supplementation in children with cystic fibrosis-a systematic review. 2016 , 175, 1255-66	28
174	Altered Fecal Microbiota Correlates with Liver Biochemistry in Nonobese Patients with Non-alcoholic Fatty Liver Disease. 2016 , 6, 32002	156
173	The role of the gut microbiota in NAFLD. 2016 , 13, 412-25	459
172	Probiotics modify tight-junction proteins in an animal model of nonalcoholic fatty liver disease. 2016 , 9, 463-72	28
171	Efficacy of probiotics in non-alcoholic fatty liver disease in adult and children: A meta-analysis of randomized controlled trials. 2016 , 46, 1226-1233	52
170	Targeting Dysbiosis for the Treatment of Liver Disease. 2016 , 36, 37-47	30

169	Probiotics in prevention and treatment of obesity: a critical view. 2016 , 13, 14	171
168	Gut Microbiota of Nonalcoholic Fatty Liver Disease. 2016 , 61, 1268-81	37
167	Changes in the Intestinal Microbiome and Alcoholic and Nonalcoholic Liver Diseases: Causes or Effects?. 2016 , 150, 1745-1755.e3	86
166	Exercise and diet in the management of nonalcoholic fatty liver disease. 2016 , 65, 1172-82	37
165	Obesity. 2016 ,	4
164	Probiotics for people with hepatic encephalopathy. 2017 , 2, CD008716	48
163	Current and future treatment options in non-alcoholic steatohepatitis (NASH). 2017 , 11, 357-369	26
162	Fecal microbiota transplantation in metabolic syndrome: History, present and future. 2017 , 8, 253-267	144
161	Significant positive association of endotoxemia with histological severity in 237 patients with non-alcoholic fatty liver disease. 2017 , 46, 175-182	40
160	Effects of Probiotics on Nonalcoholic Fatty Liver Disease in Obese Children and Adolescents. 2017 , 64, 413-417	119
159	Remote Sensing between Liver and Intestine: Importance of Microbial Metabolites. 2017 , 3, 101-113	39
158	Nonalcoholic Fatty Liver Disease, the Gut Microbiome, and Diet. 2017 , 8, 240-252	85
157	Molecules, Systems and Signaling in Liver Injury. 2017 ,	
156	The Impact of Gut Microbiota on Liver Injury. 2017 , 251-283	
155	Exploring the microbiome in health and disease: Implications for toxicology. 2017 , 1, 239784731774188	19
154	Non-alcoholic Fatty Liver Disease in Non-obese Patients. 2017 , 16, 382-390	
153	An Overview of Probiotic Research. 2017 , 293-357	1
152	Role of Probiotics in the Treatment of Nonalcoholic Fatty Liver Disease: A Meta-analysis. 2017 , 7, 130-137	33

151	Obesity and Hepatocellular Carcinoma. 2017 , 267-277	2
150	Gut Microbiota and Nonalcoholic Fatty Liver Disease: Insights on Mechanisms and Therapy. 2017 , 9,	100
149	Dietary Composition Independent of Weight Loss in the Management of Non-Alcoholic Fatty Liver Disease. 2017 , 9,	54
148	Effects of Probiotics, Prebiotics, and Synbiotics on Human Health. 2017 , 9,	793
147	Gut-liver axis: Menace in the microbiota. 2017 , 551, S94-S95	7
146	Gut-Liver Axis Derangement in Non-Alcoholic Fatty Liver Disease. 2017 , 4,	59
145	Intestinal hormones, gut microbiota and non-alcoholic fatty liver disease. 2017 , 42, 184-194	13
144	Taurine and tea polyphenols combination ameliorate nonalcoholic steatohepatitis in rats. 2017 , 17, 455	15
143	Probiotics for the Treatment of Liver Disease. 2017 , 373-381	3
142	Gut bacteria may control development of hepatocellular carcinoma. 2017 , 6, 417-419	5
141	Gut microbiota, fatty liver disease, and hepatocellular carcinoma. 2018 , 2, 43-51	44
140	Synbiotics for Improved Human Health: Recent Developments, Challenges, and Opportunities. 2018 , 9, 451-479	27
139	The Role of Prebiotics and Probiotics in Gastrointestinal Disease. 2018 , 47, 179-191	30
138	Effects of probiotics on body weight, body mass index, fat mass and fat percentage in subjects with overweight or obesity: a systematic review and meta-analysis of randomized controlled trials. 2018 , 19, 219-232	122
137	Current Treatment of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis. 2018 , 22, 175-187	21
136	Probiotics, prebiotics, synbiotics and insulin sensitivity. 2018 , 31, 35-51	105
135	Emerging metabolic risk factors in hepatocellular carcinoma and their influence on the liver microenvironment. 2018 , 1864, 607-617	26
134	Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis. 2018 , 57, 2037-2053	23

133 Intestinal Microbiome and the Liver. **2018**, 37-65.e6

132 Is It Time to Use Probiotics to Prevent or Treat Obesity?. **2018**, 10, 55

131 Blueberry, combined with probiotics, alleviates non-alcoholic fatty liver disease via IL-22-mediated JAK1/STAT3/BAX signaling. **2018**, 9, 6298-6306 18

130 Nutraceutical-Based Pharmacological Intervention in the Management of Liver Diseases. **2018**, 375-394

129 Intestinal Microbiota Modulation in Obesity-Related Non-alcoholic Fatty Liver Disease. **2018**, 9, 1813 44

128 Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease. **2018**, 24, 331-338 15

127 Pharmacological interventions for non-alcoholic fatty liver disease: a systematic review and network meta-analysis. **2018**, 94, 556-565 11

126 Gut?Liver Axis: How Do Gut Bacteria Influence the Liver?. **2018**, 6, 53

125 The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention. **2018**, 14, 701-706 17

124 Compromised nutritional status in patients with end-stage liver disease: Role of gut microbiota. **2018**, 17, 290-300 4

123 Daily Consumption of Synbiotic Yogurt Decreases Liver Steatosis in Patients with Nonalcoholic Fatty Liver Disease: A Randomized Controlled Clinical Trial. **2018**, 148, 1276-1284 54

122 Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis. **2018**, 76, 822-839 56

121 Probiotics in Gastroenterology: How Pro Is the Evidence in Adults?. **2018**, 113, 1125-1136 27

120 Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial. **2019**, 58, 1735-1745 44

119 Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease. **2019**, 50, 628-639 19

118 Probiotics for dietary management of non-alcoholic fatty liver disease. **2019**, 17, 1553-1563 8

117 Effect of probiotic supplementation in nonalcoholic steatohepatitis patients: PROBILIVER TRIAL protocol. **2019**, 20, 580 5

116 The Role of Probiotics in Nonalcoholic Fatty Liver Disease: A New Insight into Therapeutic Strategies. **2019**, 11, 42

115	Effects of probiotics on nonalcoholic fatty liver disease: a systematic review and meta-analysis. 2019 , 12, 1756284819878046		20
114	Effect of N1115 and fructooligosaccharides in nonalcoholic fatty liver disease. 2019 , 15, 1336-1344		21
113	The links between the gut microbiome and non-alcoholic fatty liver disease (NAFLD). 2019 , 76, 1541-1558		161
112	ESPEN guideline on clinical nutrition in liver disease. 2019 , 38, 485-521		202
111	Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression. 2019 , 110, 139-149		50
110	Efficacy of Probiotics and Synbiotics in Patients with Nonalcoholic Fatty Liver Disease: A Meta-Analysis. 2019 , 64, 3402-3412		33
109	Review article: emerging role of the gut microbiome in the progression of nonalcoholic fatty liver disease and potential therapeutic implications. 2019 , 50, 144-158		26
108	Reappraisal of probiotics' safety in human. 2019 , 129, 22-29		54
107	Microbiota and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (NAFLD/NASH). <i>Annals of Hepatology</i> , 2019 , 18, 416-421	3.1	28
106	Impact of Nutritional Changes on Nonalcoholic Fatty Liver Disease. 2019 , 11,		71
105	Functional Microbiomics in Liver Transplantation: Identifying Novel Targets for Improving Allograft Outcomes. 2019 , 103, 668-678		12
104	Contribution of the gut microbiota to the regulation of host metabolism and energy balance: a focus on the gut-liver axis. 2019 , 78, 319-328		44
103	The Therapeutic Implications of the Gut Microbiome and Probiotics in Patients with NAFLD. 2019 , 7,		24
102	Nonalcoholic fatty liver disease and the gut microbiome: Are bacteria responsible for fatty liver?. 2019 , 244, 408-418		9
101	Randomized, Double-blind, Placebo-controlled Study of a Multispecies Probiotic Mixture in Nonalcoholic Fatty Liver Disease. 2019 , 9, 5688		59
100	The Microbiome and Metabolome in Nonalcoholic Fatty Liver Disease. 2019 , 265-269		
99	Role of the intestinal microbiome in liver fibrosis development and new treatment strategies. 2019 , 209, 22-38		18
98	Effects of probiotic supplementation on the regulation of blood lipid levels in overweight or obese subjects: a meta-analysis. 2019 , 10, 1747-1759		21

97	Histopathological Features and Composition of Gut Microbiota in Rhesus Monkey of Alcoholic Liver Disease. 2019 , 10, 165	10
96	Role of Probiotics in Non-alcoholic Fatty Liver Disease: Does Gut Microbiota Matter?. 2019 , 11,	23
95	Systematic Review with Meta-Analysis: The Effects of Probiotics in Nonalcoholic Fatty Liver Disease. 2019 , 2019, 1484598	19
94	The promising role of probiotic and synbiotic therapy in aminotransferase levels and inflammatory markers in patients with nonalcoholic fatty liver disease - a systematic review and meta-analysis. 2019 , 31, 703-715	9
93	Inflammation and Microbiota Fingerprint: Delphi's Oracle for Nonalcoholic Fatty Liver Disease-Related Hepatocellular Carcinoma?. 2019 , 69, 12-15	3
92	Rates of and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis. 2019 , 17, 616-629.e26	53
91	Characterization of antimicrobial resistance in lactobacilli and bifidobacteria used as probiotics or starter cultures based on integration of phenotypic and in silico data. 2020 , 314, 108388	31
90	Intestinal microbiome and NAFLD: molecular insights and therapeutic perspectives. 2020 , 55, 142-158	41
89	Non-Alcoholic Fatty Liver Disease. 2020 ,	1
88	Gestational Diabetes Is Uniquely Associated With Altered Early Seeding of the Infant Gut Microbiota. 2020 , 11, 603021	9
87	Efficacy of Dietary Supplements to Reduce Liver Fat. 2020 , 12,	5
86	ESPEN practical guideline: Clinical nutrition in liver disease. 2020 , 39, 3533-3562	52
85	Microbial Metabolites: Critical Regulators in NAFLD. 2020 , 11, 567654	12
84	Recipe for a Healthy Gut: Intake of Unpasteurised Milk Is Associated with Increased Abundance in the Human Gut Microbiome. 2020 , 12,	19
83	Microbiote intestinal et stéatopathie métabolique. 2020 , 34, 130-140	
82	Gut Microbiota in Liver Disease: What Do We Know and What Do We Not Know?. 2020 , 35, 261-274	14
81	Hepatoprotective Effects of LM1012 in Mice Exposed to Air Pollutants. 2020 , 23, 852-861	3
80	Allogenic Fecal Microbiota Transplantation in Patients With Nonalcoholic Fatty Liver Disease Improves Abnormal Small Intestinal Permeability: A Randomized Control Trial. 2020 , 115, 1055-1065	72

79	Nonalcoholic Fatty Liver Disease: Modulating Gut Microbiota to Improve Severity?. 2020 , 158, 1881-1898	38
78	Synbiotics Alter Fecal Microbiomes, But Not Liver Fat or Fibrosis, in a Randomized Trial of Patients With Nonalcoholic Fatty Liver Disease. 2020 , 158, 1597-1610.e7	59
77	YRL577 combined with plant extracts reduce markers of non-alcoholic fatty liver disease in mice. 2021 , 125, 1081-1091	1
76	Epidemiology, Pathogenesis, Diagnosis and Emerging Treatment of Nonalcoholic Fatty Liver Disease. 2021 , 52, 25-37	25
75	Effects of therapeutic probiotics on modulation of microRNAs. 2021 , 19, 4	12
74	THE THERAPEUTIC IMPACT OF PROBIOTICS ON NONALCOHOLIC FATTY LIVER DISEASE IN PEDIATRICS: A SYSTEMATIC REVIEW. 2021 , 39, e2019226	2
73	Synbiotics in Nutrition. 2021 , 149-161	1
72	Therapeutic approaches for non-alcoholic steatohepatitis. 2021 , 12, 20420188211034300	1
71	Nutritional Approach Targeting Gut Microbiota in NAFLD-To Date. 2021 , 18,	3
70	Gut Microbiota in Metabolic-associated Fatty Liver Disease and in Other Chronic Metabolic Diseases. 2021 , 9, 227-238	4
69	Probiotics, Pre-biotics and Synbiotics in the Treatment of Pre-diabetes: A Systematic Review of Randomized Controlled Trials. 2021 , 9, 645035	1
68	Resveratrol Butyrate Esters Inhibit BPA-Induced Liver Damage in Male Offspring Rats by Modulating Antioxidant Capacity and Gut Microbiota. 2021 , 22,	9
67	Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy. 2021 , 22,	7
66	Nutritional supplementation for nonalcohol-related fatty liver disease: a network meta-analysis. 2021 , 7, CD013157	2
65	The impact of alteration in gut microbiome in the pathogenesis of nonalcoholic fatty liver disease. 2021 , 34, 477-482	2
64	The promise of the gut microbiome as part of individualized treatment strategies. 2021 ,	12
63	Novel approaches to intervene gut microbiota in the treatment of chronic liver diseases. 2021 , 35, e21871	5
62	Probiotics in treating with alcoholic liver disease and nonalcoholic fatty liver disease. 1-19	0

61	Polyphenolic bioactives as an emerging group of nutraceuticals for promotion of gut health: A review. 2021 , 44, 101376	6
60	The role of the gut microbiome and diet in the pathogenesis of non-alcoholic fatty liver disease. 2021 , 27, 22-43	14
59	Immunity and Gut Microbiome: Role of Probiotics and Prebiotics. 2021 , 61-83	0
58	Lactobacillus attenuates progression of nonalcoholic fatty liver disease by lowering cholesterol and steatosis. 2021 , 27, 110-124	10
57	Pathogenesis of Nonalcoholic Fatty Liver Disease. 2018 , 369-390.e14	1
56	Polyphenol supplementation benefits human health via gut microbiota: A systematic review via meta-analysis. 2020 , 66, 103829	60
55	Microbiota, NASH, HCC and the potential role of probiotics. 2017 , 38, 231-240	113
54	Therapeutic opportunities for alcoholic steatohepatitis and nonalcoholic steatohepatitis: exploiting similarities and differences in pathogenesis. 2017 , 2,	30
53	IMPACT OF CURRENT DIET AT THE RISK OF NON-ALCOHOLIC FATTY LIVER DISEASE (NAFLD). 2019 , 56, 431-439	7
52	[Liver diseases: The pathogenetic role of the gut microbiome and the potential of treatment for its modulation]. 2017 , 89, 120-128	4
51	Non alcoholic steatohepatitis a precursor for hepatocellular carcinoma development. 2014 , 20, 16464-73	30
50	Probiotic Therapy in Patients with Nonalcoholic Steatohepatitis in Zagazig University Hospitals. 2017 , 7, 101-106	19
49	The Effect of Synbiotic Supplementation on Body Composition and Lipid Profile in Patients with NAFLD: A Randomized, Double Blind, Placebo-Controlled Clinical Trial Study. 2017 , 19,	10
48	Pharmacologic Therapy for Nonalcoholic Fatty Liver Disease. 2014 , 86, 425	1
47	Non-alcoholic Fatty Liver Disease in Obesity. 2016 , 159-179	
46	Have Probiotics and Synbiotics passed the test of time to be implemented in management of obesity and related metabolic disorders-a comprehensive review. 2019 , 9, 21-28	0
45	From Two hit theory to Multiple hit theory Implications of evolution of pathogenesis concepts for treatment of non-alcoholic fatty liver disease. 2019 , 27, 1171-1178	1
44	Prebiotics, Probiotics, Synbiotics and Its Importance in the Management of Diseases. 2020 , 173-196	2

43	Etiopathogenesis of NAFLD: Diet, Gut, and NASH. 2020 , 73-95	
42	Dietary Approach to NAFLD. 2020 , 271-287	1
41	Diet and gut microbiome in fatty liver and its associated liver cancer. 2021 , 37, 7	4
40	Gut Microbiome-Mediated Alteration of Immunity, Inflammation, and Metabolism Involved in the Regulation of Non-alcoholic Fatty Liver Disease. 2021 , 12, 761836	5
39	A GLP-1/GLP-2 receptor dual agonist to treat non-alcoholic steatohepatitis: targeting the gut-liver axis and microbiome. 2021 ,	1
38	Pharmacotherapy for Non-Alcoholic Fatty Liver Disease: Emerging Targets and Drug Candidates.. 2022 , 10,	2
37	Therapeutic potential of <i>Saccharomyces boulardii</i> in liver diseases: from passive bystander to protective performer?. 2021 , 175, 106022	0
36	The crucial role of oxidative stress in non-alcoholic fatty liver disease-induced male reproductive toxicity: the ameliorative effects of Iranian indigenous probiotics.. 2022 , 395, 247	4
35	Probiotics, prebiotics and synbiotics: Safe options for next-generation therapeutics.. 2022 , 106, 505	7
34	Probiotics and obesity associated disease: an extended view beyond traditional strains.. 2021 , 67, 348-356	1
33	The Effects of Probiotics and Omega-3 Fatty Acids in Liver Steatosis Induced in Rats by High-Fructose Corn Syrup. 2022 , 2022, 1-14	
32	The Role of Gut-Liver Axis in Gut Microbiome Dysbiosis Associated NAFLD and NAFLD-HCC.. 2022 , 10,	7
31	DataSheet_1.pdf. 2020 ,	
30	Effect of Probiotics on Liver Enzymes in Patients With Non-alcoholic Fatty Liver Disease: An Umbrella of Systematic Review and Meta-Analysis. 2022 , 9,	1
29	Effects of Synbiotics, Probiotics, and Prebiotics on Liver Enzymes of Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Network Meta-Analysis. 2022 , 9,	0
28	Probiotics for liver disease prevention and treatment. 2022 , 579-588	
27	Gut firmicutes: Relationship with dietary fiber and role in host homeostasis. 1-16	3
26	Synbiotic Effects of Fermented Rice on Human Health and Wellness: A Natural Beverage That Boosts Immunity. 13,	1

25	Therapeutic mechanisms and beneficial effects of non-antidiabetic drugs in chronic liver diseases. 2022 , 28, 425-472	0
24	European guideline on obesity care in patients with gastrointestinal and liver diseases □Joint ESPEN/UEG guideline. 2022 ,	4
23	Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). 2022 , 7,	4
22	Kombucha tea improves glucose tolerance and reduces hepatic steatosis in obese mice. 2022 , 155, 113660	0
21	Editorial: Manipulation of gut microbiota as a key target to intervene on the onset and progression of digestive system diseases. 9,	0
20	Challenges in Development of Prebiotic and Probiotics. 2022 , 161-183	0
19	Oral 24-week probiotics supplementation did not decrease cardiovascular risk markers in patients with biopsy proven NASH: a double-blind placebo-controlled randomized study. 2022 , 100769	0
18	Synergy between oligosaccharides and probiotics: From metabolic properties to beneficial effects. 1-23	0
17	Intestinal microbiota in the treatment of metabolically associated fatty liver disease. 10, 11240-11251	1
16	Deciphering the role of gut metabolites in non-alcoholic fatty liver disease. 1-19	0
15	Pien Tze Huang Protects Against Non-Alcoholic Steatohepatitis by Modulating the Gut Microbiota and Metabolites in Mice. 2022 ,	0
14	Diet Modulates Gut Microbiome and Metabolites in Non-alcoholic Fatty Liver Diseases. 2023 , 131-146	0
13	Changes in Lipidomics, Metabolomics, and the Gut Microbiota in CDAA-Induced NAFLD Mice after Polyene Phosphatidylcholine Treatment. 2023 , 24, 1502	0
12	Protective Effects of Lactobacillus gasseri against High-Cholesterol Diet-Induced Fatty Liver and Regulation of Host Gene Expression Profiles. 2023 , 24, 2053	0
11	Microbiome and Obesity. 2023 , 101-131	0
10	Nonalcoholic fatty liver disease. 2023 , 83-97	0
9	Gastrointestinal disorders and intestinal bacteria: Advances in research and applications in therapy. 9,	0
8	Efficacy of probiotics on nonalcoholic fatty liver disease: A meta-analysis. 2023 , 102, e32734	0

- 7 Practical Guideline on Obesity care in patients with gastrointestinal and liver diseases [Joint ESPEN /UEG guideline. **2023**, ○
- 6 Nutraceutical approaches to non-alcoholic fatty liver disease (NAFLD): A position paper from the International Lipid Expert Panel (ILEP). **2023**, 189, 106679 ○
- 5 Non-Parenchymal Cells and the Extracellular Matrix in Hepatocellular Carcinoma in Non-Alcoholic Fatty Liver Disease. **2023**, 15, 1308 ○
- 4 Nutrition in liver disease. **2023**, 87-134 ○
- 3 Non-pharmacological treatment approach in patients with metabolic dysfunction-associated liver disease. **2023**, 343-367 ○
- 2 Metabolic-Associated Fatty Liver Disease and the Gut Microbiota. **2023**, ○
- 1 Synbiotics as Supplemental Therapy for the Alleviation of Chemotherapy-Associated Symptoms in Patients with Solid Tumours. **2023**, 15, 1759 ○